Diffusion Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

•  Aligned with FDA on Design of Phase 2 GBM Trial of TSC; Initiation Expected by End of 2022
•  Reported Positive Effects in TSC Altitude Trial
•  Ended Quarter with $28.5 million in Cash, Cash Equivalents and Marketable Securities
•  Expected Cash Runway into First Quarter of 2024

Read more at globenewswire.com